

TABLE 4

Newly FDA-approved Anticancer Agents: August 1, 2021-July 31, 2022

Type of Treatment	Generic Name	Trade Name	Mechanism of Action	Approved For
Surgery, Chemotherapy, Radiotherapy	gallium Ga 68 gozetotide	Locametz	Imaging agent	Certain type of prostate cancer
	lutetium Lu 177 vipivotide tetraxetan	Pluvicto	Therapeutic agent	Certain type of prostate cancer
	pafolacianine	Cytalux	Imaging agent	Certain type of ovarian cancer
Molecularly Targeted Therapy	asciminib	Scemblix	Cell-signaling inhibitor	Certain type of leukemia
	belzutifan	Welireg	Cell-signaling inhibitor	Several tumors associated with the von Hippel-Lindau syndrome
	crizotinib	Xalkori	Cell-signaling inhibitor	Certain type of inflammatory myofibroblastic tumors*
	dabrafenib & trametinib	Tafinlar & Mekinist	Cell-signaling inhibitors	Solid tumors carrying certain type of genetic mutation*
	ivosidenib [†]	Tibsovo	Epigenome-modifying agent	Certain type of bile duct cancer*
	mobocertinib [†]	Exkivity	Cell-signaling inhibitor	Certain type of lung cancer
	rituximab	Rituxan	Cell-lysis mediator	Certain type of lymphoma*
	sirolimus protein-bound particles	Fyarro	Cell-signaling inhibitor	Certain type of perivascular epithelioid cell tumors*
	tisotumab vedotin-tftv	Tivdak	DNA-damaging agent	Certain type of cervical cancer
	zanubrutinib	Brukinsa	Cell-signaling inhibitor	Certain type of lymphoma*
Immunotherapy	brexucabtagene autoleucel	Tecartus	Immunotherapeutic	Certain type of leukemia*
	ciltacabtagene autoleucel	Carvykti	Immunotherapeutic	Multiple myeloma
	dostarlimab-gxly [†]	Jemperli	Immunotherapeutic	Solid tumors with a specific genetic feature*
	relatlimab-rmbw	Opdualag	Immunotherapeutic	Certain type of melanoma
	tebentafusp-tebn	Kimmtrak	Immunotherapeutic	Certain type of ocular melanoma
	tisagenlecleucel	Kymriah	Immunotherapeutic	Certain type of lymphoma*

*New cancer type approved 2021-2022

[†]Requires a companion diagnostic